Limited coverage criteria – bimekizumab

Last updated on March 21, 2025

Special Authority requests can now be submitted online. It's simple and quick!

Generic name	bimekizumab
Strength & form	160 mg/mL solution for subcutaneous injection in a pre-filled syringe or pre-filled autoinjector

Special Authority criteria	Approval period
Treatment of moderate to severe plaque psoriasis, according to criteria detailed in form HLTH 5380 – Biologics for Moderate to Severe Psoriasis (PDF, 781KB), when a Special Authority request is submitted by a dermatologist	Initial: 16 weeks Renewal: 1 year

Practitioner exemptions

None

Special notes

PharmaCare covers a maximum of 56 days per fill for bimekizumab (coverage limited to one 320 mg dose every 8 weeks at maintenance dosing)

Special Authority request form(s)

Did you find what you were looking for?

The B.C. Public Service acknowledges the territories of First Nations around B.C. and is grateful to carry out our work on these lands. We acknowledge the rights, interests, priorities, and concerns of all Indigenous Peoples - First Nations, Métis, and Inuit - respecting and acknowledging their distinct cultures, histories, rights, laws, and governments.

More topics

Limited coverage criteria – bimekizumab

Generic name

Strength & form

Special Authority criteria

Approval period

Practitioner exemptions

Special notes

Special Authority request form(s)